Page 16 - Sosei Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article TOKYO and CAMBRIDGE, England, Feb. 1, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) announces it will apply its world-leading structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new strategic collaboration with Metrion Biosciences Limited ("Metrion"), the specialist ion channel CRO and drug discovery company. Ion channels are a class of integral membrane proteins that regulate the flow of ions across the cell membrane as a means of conducting signals between cells and their envi...

Share this article Share this article TOKYO and CAMBRIDGE, England, Jan. 12, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply their respective technologies to drive novel drug discovery against a challenging G protein-couple receptor (GPCR) target associated with neurological diseases. The collaboration will combine Sosei Heptares' world-leading GPCR-focused structure-based drug design platform, which has fully structurally enabled the GPCR target, providing detailed s...

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design - Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders - Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe News provided by Share this article Share this article TOKYO and CAMBRIDGE, England, Dec. 22, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565), a ...

Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System - Single-target agreement focused on small molecule agonists of GPR35, a genetically validated target for inflammatory bowel disease and other gastrointestinal immune disorders - Sosei Heptares eligible to receive an upfront payment, research funding and potential near-term development milestones of up to £34 million (US$44 million), potential downstream payments of up to £336 million (US$437 million) and tiered royalties News provided by Share this article Share this a...